Peripheral neuropathy Nervous System Diseases Other disorders of nervous system in diseases classified elsewhere
Conditions
Interventions
Topical application of Neuragen® vs placebo. Neuragen®/placebo is applied once each in random order and in a double-blind fashion. The applications are at least one week apart form each other. Pain is
Sponsors
Origin BioMed, Inc. (Canada)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Both males and females, over 21 2. Diagnosed neuropathic pain for more three months 3. Pain level between 3-8 on a 0-10 visual pain scale 4. Does not have mental and communication impairments
Exclusion criteria
Exclusion criteria: 1. Pregnant 2. Have other types of pain 3. Skin condition 4. Central nerve impairment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Foot sole pain on 11-point numerical pain scale, measured 30 minutes before and after the Neuragen®/placebo application, and tracked every hour for 8 hours. | — |
Secondary
| Measure | Time frame |
|---|---|
| Duration of pain reduction. Pain is measured 30 minutes before and after the application, and tracked every hour for 8 hours. | — |
Countries
United States of America
Outcome results
None listed